UBS O'Connor’s Legend Biotech LEGN Stock Holding History

UBS O'Connor’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,000	Closed	-$81K	–	407
2024 Q4	$81K	Buy	+20,000	New	+$828K	﹤0.01%	353

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS O'Connor's LEGN Position: Q2 2021 in Review

UBS O'Connor sold out of Legend Biotech (LEGN) in Q2 2021, closing a stake of 15,000 shares — an estimated $435K sold.

UBS O'Connor first reported a position in LEGN in Q2 2020 and held it in 2 quarters. The position peaked at $2.79M in Q2 2020. 86 funds tracked by Wall St. Rank hold LEGN as of Q2 2021.

UBS O'Connor reported no remaining Legend Biotech position as of Q2 2021 after selling out during the quarter.
UBS O'Connor sold 15,000 Legend Biotech shares in Q2 2021, an estimated $435K.
UBS O'Connor first reported a position in Legend Biotech in Q2 2020 and held it in 2 quarters.
UBS O'Connor's Legend Biotech position peaked at $2.79M in Q2 2020.
86 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2021.

Based on UBS O'Connor's 13F filing for Q2 2021, filed 13 Aug 2021.